CHICAGO, IL — For decades, a pancreatic cancer diagnosis was treated as a death sentence. The disease is notoriously silent, spreading before most patients even realize something is wrong. But on May 31, 2026, a standing ovation rang out inside a convention hall in Chicago — and it may have signaled the beginning of the end of that grim reality.

Researchers presented results from the Phase 3 RASolute 302 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting, showing that a once-daily oral pill called daraxonrasib nearly doubled survival in patients with advanced pancreatic cancer — from 6.7 months on standard chemotherapy to 13.2 months.

▶ THE NUMBERS THAT SHOCKED ONCOLOGISTS

The trial enrolled 500 patients with previously treated metastatic pancreatic cancer across sites in North America, Europe, and Asia. Those who took daraxonrasib were 60% less likely to die compared to patients on chemotherapy.

Lead investigator Brian Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute in Boston, called it the first RAS inhibitor to succeed in a large, randomized trial. "This is the first RAS inhibitor evaluated in a large, randomized trial for patients with pancreatic cancer," Wolpin said. "It demonstrates how important an impact these novel medicines are likely to have."

The results were published simultaneously in The New England Journal of Medicine — one of the most respected journals in medicine — amplifying the significance of the announcement.

▶ WHY THIS MATTERS IN NEW YORK, LA, HOUSTON, AND CHICAGO

Pancreatic cancer is the third-leading cause of cancer deaths in the United States, killing roughly 53,000 Americans every year. In major metro areas, the burden is substantial: the disease disproportionately affects older adults, and with large aging populations in cities like New York, Los Angeles, Chicago, and Houston, the impact of a new standard of care could be felt widely.

In Los Angeles County alone, where the population tops 10 million, cancer is the second leading cause of death. New York City — home to more than 8.3 million residents — sees thousands of new pancreatic cancer cases diagnosed annually. For these communities, a drug that doubles survival time is not merely a clinical milestone. It is a lifeline.

Read more

▶ HOW DARAXONRASIB WORKS

More than 90% of pancreatic cancers are driven by a mutated protein called KRAS, which for decades was considered "undruggable." Scientists simply could not find a way to block it without harming healthy cells.

Daraxonrasib takes a novel approach. Rather than attacking KRAS directly, it binds to a helper molecule called cyclophilin A, which then blocks KRAS from signaling cancer cells to multiply. What sets it apart is its ability to target multiple KRAS mutation variants — meaning it could work for nearly all patients with the disease, regardless of the specific genetic subtype.

The drug is taken orally — one pill per day — eliminating the need for intravenous infusions at a cancer center. That convenience could be transformative for patients in sprawling metro areas where hospital commutes are already a barrier to care.

▶ WHAT COMES NEXT

On May 1, 2026, the FDA granted permission for Revolution Medicines — the company behind the drug — to begin an expanded access program, allowing patients with previously treated metastatic pancreatic cancer to access daraxonrasib before full approval.

Experts expect daraxonrasib to become the new standard of care for second-line treatment, and trials are already underway testing it in combination with other therapies to prevent tumors from developing resistance.

For patients, families, and oncologists across America's largest cities, this is not just a research breakthrough — it is a turning point in one of medicine's hardest battles.